Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 20/20 | 0.75 |
| ▸ | MMP2 | P08253 | 5/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19692287 | 0.86 | ADAMTS5 (1.00) | ADAMTS5MMP2MMP13ADAMTS4MMP14 | |
| SCHEMBL19701804 | 0.86 | ADAMTS5 (1.00) | ADAMTS5MMP2MMP13ADAMTS4MMP14 | |
| SCHEMBL19691662 | 0.86 | ADAMTS5 (1.00) | ADAMTS5MMP2MMP13ADAMTS4MMP14 | |
| SCHEMBL21403939 | 0.86 | ADAMTS5 (1.00) | ADAMTS5MMP2MMP13ADAMTS4MMP14 | |
| SCHEMBL19702771 | 0.79 | ADAMTS5 (0.72) | ADAMTS5MMP2MMP13 | |
| SCHEMBL19701927 | 0.79 | ADAMTS5 (0.80) | ADAMTS5MMP2MMP13ADAMTS4MMP14 | |
| SCHEMBL19702770 | 0.79 | ADAMTS5 (1.00) | ADAMTS5MMP2 | |
| SCHEMBL19996703 | 0.75 | ADAMTS5 (0.74) | ADAMTS5MMP2MMP13ADAMTS4MMP14 | |
| SCHEMBL19996714 | 0.75 | ADAMTS5 (0.74) | ADAMTS5MMP2MMP13ADAMTS4MMP14 | |
| SCHEMBL23745300 | 0.72 | ADAMTS5 (0.49) | ADAMTS5MMP2MMP13ADAMTS4MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | GALAPAGOS NV (BE) | 2020-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550100-B2 | 5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis | ADAMTS5, ADAMTS4, ADAMTS1 | ADAMTS5 1/4885MMP2 31/4885MMP13 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.